Bank of America’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $111M | Sell |
452,491
-145,600
| -24% | -$31.6M | 0.01% | 1114 |
|
|
2026
Q1 | $101M | Sell |
598,091
-19,942
| -3% | -$3.44M | 0.01% | 1111 |
|
|
2025
Q4 | $113M | Buy |
618,033
+256,772
| +71% | +$35.8M | 0.01% | 1029 |
|
|
2025
Q3 | $43.9M | Sell |
361,261
-392,168
| -52% | -$44.2M | ﹤0.01% | 1866 |
|
|
2025
Q2 | $78.7M | Buy |
753,429
+219,527
| +41% | +$23.2M | 0.01% | 1328 |
|
|
2025
Q1 | $62.3M | Buy |
533,902
+329,315
| +161% | +$37.5M | 0.01% | 1401 |
|
|
2024
Q4 | $17.3M | Sell |
204,587
-522,941
| -72% | -$48.1M | ﹤0.01% | 2435 |
|
|
2024
Q3 | $65.4M | Sell |
727,528
-163,457
| -18% | -$14.3M | 0.01% | 1348 |
|
|
2024
Q2 | $71.7M | Buy |
890,985
+705,272
| +380% | +$52.2M | 0.01% | 1214 |
|
|
2024
Q1 | $14.8M | Buy |
185,713
+9,546
| +5% | +$801K | ﹤0.01% | 2580 |
|
|
2023
Q4 | $14M | Buy |
176,167
+139,041
| +375% | +$9.3M | ﹤0.01% | 2506 |
|
|
2023
Q3 | $2.59M | Buy |
37,126
+8,106
| +28% | +$606K | ﹤0.01% | 4022 |
|
|
2023
Q2 | $2.09M | Sell |
29,020
-3,517
| -11% | -$259K | ﹤0.01% | 4197 |
|
|
2023
Q1 | $2.01M | Buy |
32,537
+1,311
| +4% | +$86.1K | ﹤0.01% | 4348 |
|
|
2022
Q4 | $2.41M | Sell |
31,226
-7,023
| -18% | -$420K | ﹤0.01% | 4089 |
|
|
2022
Q3 | $1.71M | Sell |
38,249
-16,367
| -30% | -$818K | ﹤0.01% | 4425 |
|
|
2022
Q2 | $2.09M | Buy |
54,616
+9,296
| +21% | +$294K | ﹤0.01% | 4262 |
|
|
2022
Q1 | $1.88M | Buy |
45,320
+8,496
| +23% | +$263K | ﹤0.01% | 4652 |
|
|
2021
Q4 | $1.39M | Sell |
36,824
-3,390
| -8% | -$125K | ﹤0.01% | 4929 |
|
|
2021
Q3 | $1.32M | Buy |
40,214
+11,133
| +38% | +$434K | ﹤0.01% | 4812 |
|
|
2021
Q2 | $1.96M | Sell |
29,081
-1,183
| -4% | -$71K | ﹤0.01% | 4336 |
|
|
2021
Q1 | $1.71M | Buy |
30,264
+5,263
| +21% | +$370K | ﹤0.01% | 4388 |
|
|
2020
Q4 | $2.04M | Buy |
25,001
+14,024
| +128% | +$1.05M | ﹤0.01% | 3935 |
|
|
2020
Q3 | $781K | Sell |
10,977
-6,391
| -37% | -$498K | ﹤0.01% | 4387 |
|
|
2020
Q2 | $1.43M | Sell |
17,368
-1,694
| -9% | -$130K | ﹤0.01% | 3864 |
|
|
2020
Q1 | $1.12M | Sell |
19,062
-4,385
| -19% | -$357K | ﹤0.01% | 3938 |
|
|
2019
Q4 | $2.42M | Buy |
23,447
+567
| +2% | +$22.9K | ﹤0.01% | 3872 |
|
|
2019
Q3 | $463K | Sell |
22,880
-5,743
| -20% | -$148K | ﹤0.01% | 5137 |
|
|
2019
Q2 | $737K | Buy |
+28,623
| New | +$574K | ﹤0.01% | 4793 |
|
|
2019
Q1 | – | Sell |
-2,327
| Closed | -$7K | – | 7091 |
|
|
2018
Q4 | $7K | Buy |
+2,327
| New | +$7.66K | ﹤0.01% | 6694 |
|
|
2017
Q4 | – | Sell |
-226
| Closed | -$1K | – | 7021 |
|
|
2017
Q3 | $1K | Sell |
226
-4,156
| -95% | -$22.3K | ﹤0.01% | 6910 |
|
|
2017
Q2 | $24K | Buy |
4,382
+1,101
| +34% | +$4.61K | ﹤0.01% | 6161 |
|
|
2017
Q1 | $13K | Buy |
3,281
+1,754
| +115% | +$8.38K | ﹤0.01% | 6458 |
|
|
2016
Q4 | $10K | Buy |
1,527
+1,028
| +206% | +$7.22K | ﹤0.01% | 6549 |
|
|
2016
Q3 | $4K | Sell |
499
-882
| -64% | -$6.68K | ﹤0.01% | 6664 |
|
|
2016
Q2 | $10K | Buy |
+1,381
| New | +$12.7K | ﹤0.01% | 6486 |
|
Other funds holding AXSM
DTC
Bank of America's AXSM Position: Q2 2026 in Review
Bank of America reduced its Axsome Therapeutics (AXSM) stake by 24% in Q2 2026, selling an estimated $31.6M and leaving 452,491 shares worth $111M. The position accounts for 0.01% of the portfolio, ranked #1114.
Bank of America first reported a position in AXSM in Q2 2016 and has held it in 36 quarters since. The position peaked at $113M in Q4 2025. 504 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.
- Bank of America held 452,491 shares of Axsome Therapeutics worth $111M as of Q2 2026.
- Bank of America sold 145,600 Axsome Therapeutics shares in Q2 2026, an estimated $31.6M.
- Axsome Therapeutics made up 0.01% of Bank of America's portfolio in Q2 2026, its #1114 holding.
- Bank of America first reported a position in Axsome Therapeutics in Q2 2016 and has held it in 36 quarters since.
- Bank of America's Axsome Therapeutics position peaked at $113M in Q4 2025.
- 504 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.
Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.